Second generation antidepressants

Author’s reply to Straton

BMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e2284 (Published 27 March 2012)
Cite this as: BMJ 2012;344:e2284

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Gerald Gartlehner, clinical epidemiologist1
  1. 1RTI-UNC Evidence-based Practice Center (USA), Austrian Cochrane Branch, 3500 Krems, Austria
  1. gerald.gartlehner{at}donau-uni.ac.at

Straton raises an interesting point, but his conclusion loses sight of an important factor in any statistical analysis—uncertainty.1 2 All fluvoxamine comparisons (in our 2008 and 2011 reviews) are encompassed by substantial uncertainty, as shown by …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL